Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2005

View Archived Issues

Immune modulation therapy with Celacade benefits heart failure patients

Oral pimecrolimus reported effective in moderate to severe atopic dermatitis

Patupilone activity, safety gauged in phase I/II trial in non-small cell lung cancer

OGX-011 reported to be well tolerated when added to NSCLC chemotherapy

Malignant pleural mesothelioma patients achieve disease control with vinflunine

Caspase inhibitor prevents plaque progression in atherosclerotic mice

Novel adenosine A3 receptor antagonists reported

NO moiety in statins improves their therapeutic potential

Priority review for Exjade in Canada

SPA agreement for phase III study of renzapride for c-IBS

7TM Pharma begins phase I/II trials for TM-30338 for obesity

Astex Technology changes name to Astex Therapeutics

Albany Molecular Research partners with NINDS in spinal muscular atrophy

Tracleer study shows benefit in Eisenmenger's syndrome

Phase IIIb/IV ASSENT 4 PCI study of tenecteplase stopped early

MVA smallpox vaccine MVA-3000 begins phase II trial

Pagoclone studied in phase II trial for persistent developmental stuttering

Triglide launched in U.S.

VNS Therapy System receives FDA approval for treatment-resistant depression

Thelin NDA receives March 2006 action date

MATCHED study of MC-4232 completes treatment period

Novartis to acquire Bristol-Myers Squibb's OTC portfolio

Prous Science announces publication of a comprehensive review on Behcet's disease

NMP22 BladderChek Test approved in Japan

Recent patents cover therapeutic agents for cognitive impairment and neurodegeneration

Novel antithrombotic agents reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...